JY
ORIC icon

Jeff Yass’s Oric Pharmaceuticals ORIC Stock Holding History

Jeff Yass’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94M Buy
178,700
+107,400
+151% +$974K ﹤0.01% 6550
2026
Q1 		$903K Buy
71,300
+39,800
+126% +$452K ﹤0.01% 8146
2025
Q4 		$258K Buy
+31,500
New +$363K ﹤0.01% 10304
2025
Q3 		– Sell
-13,900
Closed -$141K – 13486
2025
Q2 		$141K Buy
+13,900
New +$93.3K ﹤0.01% 11545
2025
Q1 		– Sell
-44,100
Closed -$356K – 13189
2024
Q4 		$356K Buy
+44,100
New +$405K ﹤0.01% 9453
2024
Q2 		– Sell
-199,800
Closed -$2.75M – 12903
2024
Q1 		$2.75M Buy
199,800
+165,900
+489% +$1.97M ﹤0.01% 4678
2023
Q4 		$312K Buy
33,900
+23,300
+220% +$168K ﹤0.01% 9757
2023
Q3 		$64.1K Sell
10,600
-21,600
-67% -$177K ﹤0.01% 11185
2023
Q2 		$250K Buy
32,200
+11,800
+58% +$67K ﹤0.01% 9814
2023
Q1 		$116K Sell
20,400
-94,600
-82% -$494K ﹤0.01% 11162
2022
Q4 		$677K Sell
115,000
-2,100
-2% -$7.09K ﹤0.01% 7102
2022
Q3 		$375K Sell
117,100
-25,900
-18% -$104K ﹤0.01% 9228
2022
Q2 		$641K Buy
143,000
+101,700
+246% +$406K ﹤0.01% 7658
2022
Q1 		$221K Buy
+41,300
New +$372K ﹤0.01% 10998

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's ORIC Position: Q2 2026 in Review

Jeff Yass increased its Oric Pharmaceuticals (ORIC) stake by 504% in Q2 2026, buying an estimated $1.05M and bringing the position to 139,266 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #7155.

Jeff Yass first reported a position in ORIC in Q1 2021 and has held it in 20 quarters since. 179 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Jeff Yass held 139,266 shares of Oric Pharmaceuticals worth $1.51M as of Q2 2026.
  • Jeff Yass bought 116,211 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Oric Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7155 holding.
  • Jeff Yass first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • 179 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.